API Supply: COVID-19 Industry Update

API Supply Quick Facts:
The U.S. accounts for approximately 38% or $485 billion of the global pharmaceutical market of $1.2 trillion in 2018, according to the IQVIA Institute for Human Data Science.

Approximately 28% of manufacturing facilities making active pharmaceutical ingredients (APIs) for the U.S. market are based in the U.S. The remaining 72% of API manufacturers supplying the U.S. market are outside the U.S., this includes 13% in China.

Outside the U.S., the EU represents the largest source of APIs manufactured for U.S.-marketed drugs at 26%. India represents 18% of APIs supplied to the U.S.

According to the FDA’s Center for Drug Evaluation and Research, API manufacturing facilities for all drugs: 230 or 13% are in China, 510 or 28% are in the U.S., and 1,048 or 59% are ROW.

API facilities for the 370 Essential U.S. Marketed Medicines as per WHO: 15% are in China, 21% are in the U.S., and 64% are ROW.

The FDA has identified approximately 20 drugs which solely source their active pharmaceutical ingredients or finished drug products from China.

March 2: The FDA announced that a manufacturer alerted the FDA to a shortage of an undisclosed drug that was recently added to the drug shortages list. The manufacturer notified the FDA that this shortage is related to a site affected by coronavirus. The shortage is due to an issue with manufacturing of an active pharmaceutical ingredient (API) used in the drug.

As previously communicated, the FDA has been monitoring the supply chain with the expectation that the COVID-19 outbreak would likely impact the medical product supply chain, including potential disruptions to supply or shortages of critical medical products in the U.S.

Since January 24, the FDA has been in touch with more than 180 manufacturers of human drugs, not only to remind them of applicable legal requirements for notifying the FDA of any anticipated supply disruptions, but also asking them to evaluate their entire supply chain, including APIs and other components manufactured in China.

February 25: The FDA provided an update on FDA-wide activities related to the novel coronavirus outbreak: COVID-19. FDA inspections in China and the agency's oversight of imported products from China, have been impacted by this outbreak.

While the FDA is not able to conduct inspections in China right now, it continues to monitor the global drug supply chain by prioritizing risk-based inspections in other parts of the world. The FDA is not currently conducting inspections in China in response to the U.S. Department of State's Travel Advisory to not travel to China due to the novel coronavirus outbreak.  

As part of the agency's risk-based approach to ensuring quality and compliance, the FDA uses other tools to help complement inspections, including import screening, examinations, sampling, and import alerts, relying on a firm's previous compliance history, and information from foreign governments as part of mutual recognition agreements.

Statement from the FDA
Coronavirus (COVID-19):  FDA continues to take steps to monitor the supply chain. The CDER Drug Shortage Staff has asked manufactures to evaluate their entire supply chain, including active pharmaceutical ingredients, finished dose forms, and any components that may be impacted in China or in other areas of the supply chain due to the Coronavirus (COVID-19).  For the latest information from FDA on the Coronavirus (COVID-19) see website: Novel coronavirus (COVID-19).

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.